Summary: Allergic rhinitis affects approximately 9 million people in Poland, and despite the availability of established treatments, disease control in everyday clinical practice remains suboptimal. Olopatadine-Mometasone the first fixed-dose combination of mometasone furoate (25 µg) and olopatadine (600 µg) in a single intranasal spray registered in Poland was developed precisely in response to this unmet need. The preparation is indicated for patients aged 12 years and older with symptomatic allergic rhinitis and combines two complementary mechanisms of action: rapid H1-receptor blockade by olopatadine together with the sustained, systemically safe anti-inflammatory effect of mometasone. Furthermore, the formulation is not merely a simple mixture of two known substances – it is distinguished by high viscosity, strong adhesion to the nasal mucosa, and deeper drug deposition in the middle and upper turbinates compared with other intranasal aerosols available on the Polish market. Clinical data from seven trials including two Phase III studies in seasonal allergic rhinitis, a 52-week observation in perennial allergic rhinitis, a 2026 observational study, and a Polish real-world study involving more than 2,100 patients consistently demonstrate that the mometasone-olopatadine combination acts more rapidly (relief within 15 minutes) and more effectively than monotherapy with either component in terms of nasal symptoms, ocular symptoms, and quality of life. The ARIA 2024–2025 guidelines have for the first time issued a conditional recommendation in favour of the INAH + INCS combination over corticosteroid monotherapy alone, citing faster onset of action and greater patient satisfaction as key arguments.